Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Increasing Physical Activity Among Breast Cancer Survivors With Depression
Increasing Physical Activity Among Breast Cancer Survivors With Depression
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
349
mi
from
Dallas, TX
Increasing Physical Activity Among Breast Cancer Survivors With Depression
Increasing Physical Activity Among Breast Cancer Survivors With Depression
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
349
mi
from
Dallas, TX
Click here to add this to my saved trials
Genomics in Michigan Impacting Observation or Radiation
Genomics in Michigan Impacting Observation or Radiation (G-MINOR)
Status: Enrolling
Updated:  12/31/1969
University of Michigan Hospital and Health Systems
810
mi
from
Ann Arbor, MI
Genomics in Michigan Impacting Observation or Radiation
Genomics in Michigan Impacting Observation or Radiation (G-MINOR)
Status: Enrolling
Updated: 12/31/1969
University of Michigan Hospital and Health Systems
810
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen
A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen
Status: Enrolling
Updated:  12/31/1969
National Cancer Institute , 9000 Rockville Pike
1123
mi
from
Bethesda, MD
A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen
A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen
Status: Enrolling
Updated: 12/31/1969
National Cancer Institute , 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Identification of Prostate Cancer Genes
Genetic Analysis of Cases, Controls, and Families With Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Identification of Prostate Cancer Genes
Genetic Analysis of Cases, Controls, and Families With Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Status: Enrolling
Updated:  12/31/1969
NYU Laura and Isaac Perlmutter Cancer Center Laura & Isaac Perlmutter Ctr
1288
mi
from
New York, NY
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Status: Enrolling
Updated: 12/31/1969
NYU Laura and Isaac Perlmutter Cancer Center Laura & Isaac Perlmutter Ctr
1288
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
788
mi
from
Marietta, GA
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
788
mi
from
Marietta, GA
Click here to add this to my saved trials
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
841
mi
from
Detroit, MI
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
841
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Status: Enrolling
Updated:  12/31/1969
Novartis
1114
mi
from
Fairfax, VA
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Status: Enrolling
Updated: 12/31/1969
Novartis
1114
mi
from
Fairfax, VA
Click here to add this to my saved trials
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Guangzhou,
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Guangzhou,
Click here to add this to my saved trials
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
572
mi
from
Houston, TX
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
572
mi
from
Houston, TX
Click here to add this to my saved trials
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
4940
mi
from
Lyon,
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
4940
mi
from
Lyon,
Click here to add this to my saved trials
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
UAB Comprehensive Cancer Center
684
mi
from
Birmingham, AL
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
UAB Comprehensive Cancer Center
684
mi
from
Birmingham, AL
Click here to add this to my saved trials
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis
Status: Enrolling
Updated:  12/31/1969
Northwestern University
611
mi
from
Chicago, IL
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis
Status: Enrolling
Updated: 12/31/1969
Northwestern University
611
mi
from
Chicago, IL
Click here to add this to my saved trials
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis
Status: Enrolling
Updated:  12/31/1969
Northwestern Lake Forest Hospital
mi
from
Lake Forest, IL
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis
Status: Enrolling
Updated: 12/31/1969
Northwestern Lake Forest Hospital
mi
from
Lake Forest, IL
Click here to add this to my saved trials
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis
Status: Enrolling
Updated:  12/31/1969
Houston Methodist Hospital/Houston Methodist Cancer Center
572
mi
from
Houston, TX
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis
Status: Enrolling
Updated: 12/31/1969
Houston Methodist Hospital/Houston Methodist Cancer Center
572
mi
from
Houston, TX
Click here to add this to my saved trials
A mHealth Behavioral Cancer Pain Protocol for Medically Underserved Communities
A mHealth Behavioral Cancer Pain Protocol for Medically Underserved Communities.
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
1052
mi
from
Durham, NC
A mHealth Behavioral Cancer Pain Protocol for Medically Underserved Communities
A mHealth Behavioral Cancer Pain Protocol for Medically Underserved Communities.
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
1341
mi
from
San Francisco, CA
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
1341
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
1206
mi
from
Fort Myers, FL
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
1206
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
Loyola University Medical Center
600
mi
from
Maywood, IL
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
Loyola University Medical Center
600
mi
from
Maywood, IL
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute
841
mi
from
Detroit, MI
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute
841
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
Washington University Medical Center
415
mi
from
Saint Louis, MO
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
Washington University Medical Center
415
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
SUNY Stony Brook
1358
mi
from
Stony Brook, NY
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
SUNY Stony Brook
1358
mi
from
Stony Brook, NY
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
1225
mi
from
Philadelphia, PA
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
1229
mi
from
Philadelphia, PA
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
1229
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
Hasbro Children's Hospital
1424
mi
from
Providence, RI
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
Hasbro Children's Hospital
1424
mi
from
Providence, RI
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Cancer Center
618
mi
from
Nashville, TN
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Cancer Center
618
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology, PLLC
558
mi
from
Nashville, TN
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology, PLLC
558
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
618
mi
from
Nashville, TN
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
618
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
5602
mi
from
Buenos Aires,
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
5602
mi
from
Buenos Aires,
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
Arizona Cancer Center
835
mi
from
Tucson, AZ
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
Arizona Cancer Center
835
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
USC Norris Cancer Hospital
1166
mi
from
Los Angeles, CA
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
USC Norris Cancer Hospital
1166
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
University of Southern Florida School of Medicine
1113
mi
from
Gainesville, FL
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
University of Southern Florida School of Medicine
1113
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
1119
mi
from
Saint Petersburg, FL
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
1119
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
1127
mi
from
Washington,
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
1127
mi
from
Washington,
Click here to add this to my saved trials
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
1145
mi
from
Sarasota, FL
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
1145
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Winship Cancer Center Emory University
801
mi
from
Atlanta, GA
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Winship Cancer Center Emory University
801
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
New York Univ. Medical Center
1286
mi
from
New York, NY
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
New York Univ. Medical Center
1286
mi
from
New York, NY
Click here to add this to my saved trials
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Columbia University College of Phys & Surgeons
1290
mi
from
New York, NY
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Columbia University College of Phys & Surgeons
1290
mi
from
New York, NY
Click here to add this to my saved trials
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Cancer Center
618
mi
from
Nashville, TN
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Cancer Center
618
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology, PLLC
558
mi
from
Nashville, TN
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology, PLLC
558
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute at HealthONE
408
mi
from
Denver, CO
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute at HealthONE
408
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Universitair Ziekenhuis Antwerpen
4710
mi
from
Edegem,
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Universitair Ziekenhuis Antwerpen
4710
mi
from
Edegem,
Click here to add this to my saved trials
Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer
Colonoscopy Screening Trial
Status: Enrolling
Updated:  12/31/1969
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
423
mi
from
Shreveport, LA
Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer
Colonoscopy Screening Trial
Status: Enrolling
Updated: 12/31/1969
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
423
mi
from
Shreveport, LA
Click here to add this to my saved trials
Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer
Colonoscopy Screening Trial
Status: Enrolling
Updated:  12/31/1969
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer
Colonoscopy Screening Trial
Status: Enrolling
Updated: 12/31/1969
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer
Colonoscopy Screening Trial
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer
Colonoscopy Screening Trial
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Click here to add this to my saved trials
Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer
Colonoscopy Screening Trial
Status: Enrolling
Updated:  12/31/1969
Group Health Capitol Hill Campus
1409
mi
from
Seattle, WA
Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer
Colonoscopy Screening Trial
Status: Enrolling
Updated: 12/31/1969
Group Health Capitol Hill Campus
1409
mi
from
Seattle, WA
Click here to add this to my saved trials
The Active After Cancer Trial (AACT)
Pilot Study of a Multicenter, Telephone-Based Exercise Intervention for Patients With Early-Stage Breast and Colorectal Cancer: The Active After Cancer Trial (AACT)
Status: Enrolling
Updated:  12/31/1969
The University of California, San Diego
1145
mi
from
La Jolla, CA
The Active After Cancer Trial (AACT)
Pilot Study of a Multicenter, Telephone-Based Exercise Intervention for Patients With Early-Stage Breast and Colorectal Cancer: The Active After Cancer Trial (AACT)
Status: Enrolling
Updated: 12/31/1969
The University of California, San Diego
1145
mi
from
La Jolla, CA
Click here to add this to my saved trials
The Active After Cancer Trial (AACT)
Pilot Study of a Multicenter, Telephone-Based Exercise Intervention for Patients With Early-Stage Breast and Colorectal Cancer: The Active After Cancer Trial (AACT)
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
1341
mi
from
San Francisco, CA
The Active After Cancer Trial (AACT)
Pilot Study of a Multicenter, Telephone-Based Exercise Intervention for Patients With Early-Stage Breast and Colorectal Cancer: The Active After Cancer Trial (AACT)
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
1341
mi
from
San Francisco, CA
Click here to add this to my saved trials
The Active After Cancer Trial (AACT)
Pilot Study of a Multicenter, Telephone-Based Exercise Intervention for Patients With Early-Stage Breast and Colorectal Cancer: The Active After Cancer Trial (AACT)
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
The Active After Cancer Trial (AACT)
Pilot Study of a Multicenter, Telephone-Based Exercise Intervention for Patients With Early-Stage Breast and Colorectal Cancer: The Active After Cancer Trial (AACT)
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
Click here to add this to my saved trials
The Active After Cancer Trial (AACT)
Pilot Study of a Multicenter, Telephone-Based Exercise Intervention for Patients With Early-Stage Breast and Colorectal Cancer: The Active After Cancer Trial (AACT)
Status: Enrolling
Updated:  12/31/1969
New Hampshire Oncology-Hematology, PA
1423
mi
from
Concord, NH
The Active After Cancer Trial (AACT)
Pilot Study of a Multicenter, Telephone-Based Exercise Intervention for Patients With Early-Stage Breast and Colorectal Cancer: The Active After Cancer Trial (AACT)
Status: Enrolling
Updated: 12/31/1969
New Hampshire Oncology-Hematology, PA
1423
mi
from
Concord, NH
Click here to add this to my saved trials